Perceptions of COVID-19 Vaccination among Organ Transplant Recipients DOI Open Access
Alexis Hope Lerner, Panos Arvanitis, Dorra Guermazi

и другие.

Опубликована: Апрель 16, 2024

Understanding vaccine hesitancy in organ transplant recipients (OTR) is critical, given clear, alt-hough attenuated, benefits from vaccination. Adult OTR were surveyed regarding vaccine-related values and a novel outcome variable called Vaccine Acceptance Composite Score (VACS) was built as the average Likert score of 7 domains vaccination confidence. Of 46 included (93.5% kidney recipients), 32.6% female, 13.3% Black, 6.77% Hispan-ic/Latino/a/x; median age 58 years. Patients most concerned about COVID-19 vac-cine-associated risks (46.3%), its potential effect on allograft (47.6%) motives government officials involved with policy (55.6%). Politically conservative patients likely to have significantly lower VACS, while those who lived someone ≥65 had higher VACS. The VACS not associated race, income, religious beliefs, comorbidities, history, or influenza status. Higher ≥3 ≥4 immunizations. This study highlighted political beliefs elderly household members correlates acceptance among OTR. may be useful tool help standardize multifaceted analyses vaccination-focused behavioral research, well identify individuals groups at risk for hesitancy, benefit tai-lored outreach educational interventions.

Язык: Английский

Epidemic spreading on higher-order networks DOI
Wei Wang, Yanyi Nie, Wenyao Li

и другие.

Physics Reports, Год журнала: 2024, Номер 1056, С. 1 - 70

Опубликована: Янв. 19, 2024

Язык: Английский

Процитировано

65
Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023 DOI Creative Commons
Javier T Solera, Berta G. Árbol, Ankit Mittal

и другие.

American Journal of Transplantation, Год журнала: 2024, Номер 24(7), С. 1303 - 1316

Опубликована: Март 17, 2024

Data regarding coronavirus disease 2019 (COVID-19) outcomes in solid organ transplant recipients (SOTr) across severe acute respiratory syndrome 2 (SARS-CoV-2) waves, including the impact of different measures, are lacking. This cohort study, conducted from March 2020 to May 2023 Toronto, Canada, aimed analyze COVID-19 1975 SOTr various SARS-CoV-2 waves and assess preventive treatment measures. The primary outcome was COVID-19, defined as requiring supplemental oxygen, with secondary hospitalization, length stay, intensive care unit (ICU) admission, 30-day 1-year all-cause mortality. were categorized Wildtype/Alpha/Delta (318 cases, 16.1%), Omicron BA.1 (268, 26.2%), BA.2 13.6%), BA.5 (561, 28.4%), BQ.1.1 (188, 9.5%), XBB.1.5 (123, 6.2%). Severe rate highest during wave (44.6%), lower (5.7%-16.1%). Lung transplantation associated (OR: 4.62, 95% CI: 2.71-7.89), along rituximab 4.24, 1.04-17.3), long-term corticosteroid use 3.11, 1.46-6.62), older age 1.51, 1.30-1.76), chronic lung 2.11, 1.36-3.30), kidney 2.18, 1.17-4.07), diabetes 1.97, 1.37-2.83). Early ≥3 vaccine doses reduced severity 0.29, 0.19-0.46, 0.35, 0.21-0.60, respectively). Tixagevimab/cilgavimab bivalent boosters did not show a significant impact. study concludes that decreased variants SOTr. worse may benefit more early therapeutic interventions.

Язык: Английский

Процитировано

18
Excess mortality in COVID-19-affected solid organ transplant recipients across the pandemic DOI Creative Commons
Shigeyoshi Yamanaga, Keita Shimata, Satoko Ohfuji

и другие.

American Journal of Transplantation, Год журнала: 2024, Номер 24(8), С. 1495 - 1508

Опубликована: Март 20, 2024

The excess mortality of coronavirus disease 2019 (COVID-19) solid organ transplant recipients (SOTRs) throughout the pandemic remains unclear. This prospective cohort study based on Japanese nationwide registry included 1632 SOTRs diagnosed with COVID-19 between February 1, 2020, and July 31, 2022, categorized dominant phases variants concern (VOCs): Waves 1 to 3 (Beta), 4 (Alpha), 5 (Delta), 6 (Omicron BA.1/BA.2), 7 BA.5). Excess COVID-19-affected was analyzed by calculating standardized ratios (SMRs). Overall, COVID-19-confirmed 1170 kidney, 408 liver, 25 lung, 20 heart, small intestine, 8 multiorgan recipients. Although severity all-cause decreased as VOCs transitioned, SMRs were consistently higher than those general population pandemic, showing a U-shaped gap that peaked toward Omicron BA.5 phase; SMR (95% CI): 6.2 (3.1-12.5), 4.0 (1.5-10.6), 3.0 (1.3-6.7), 8.8 (5.3-14.5), 21.9 (5.5-87.6) for Wave BA.1/2), BA.5), respectively. In conclusion, had greater across pandemic. Vaccine boosters, immunosuppression optimization, other protective measures, particularly older SOTRs, are paramount.

Язык: Английский

Процитировано

8
Azvudine versus Paxlovid in COVID‐19: A systematic review and meta‐analysis DOI
Behnam Amani, Bahman Amani

Reviews in Medical Virology, Год журнала: 2024, Номер 34(4)

Опубликована: Июнь 7, 2024

Abstract This systematic review and meta‐analysis aimed to compare the effectiveness safety of azvudine versus nirmatrelvir/ritonavir (Paxlovid) in treating coronavirus disease 2019 (COVID‐19). The researchers conducted searches on PubMed, Cochrane Library, Web Science, medRxiv, Google Scholar until January 2024. risk bias tool was utilised evaluate quality included studies, data analysis performed using Comprehensive Meta‐Analysis software. Thirteen including 4949 patients, were analysed. results showed no significant difference between Paxlovid groups terms mortality rate (odds [OR] = 0.84, 95% confidence interval [CI]: 0.59–1.21), negative polymerase chain reaction (PCR) conversion time (standard mean [SMD] 1.52, CI: −1.07–4.11), hospital stay (SMD −0.39, −1.12–0.33). However, a observed two intensive care unit admission (OR 0.42, 0.23–0.75) need for mechanical ventilation 0.61, 0.44–0.86) favour azvudine. incidence adverse events group significantly lower 0.66, 0.43–0.99). certainty evidence rated as low moderate. Azvudine demonstrated similar reducing rates, PCR stay. better improving other outcomes. Regarding level evidence, further research is needed validate or challenge these results.

Язык: Английский

Процитировано

5
Efficacy and safety of COVID-19 vaccination in solid organ transplant recipients: A systematic review and network meta-analysis DOI Creative Commons
Daniel Rayner, Jairo Tavares Nunes, David Gou

и другие.

American Journal of Transplantation, Год журнала: 2024, Номер 24(12), С. 2269 - 2281

Опубликована: Авг. 1, 2024

The impact of COVID-19 vaccination on clinical outcomes in solid organ transplant (SOT) recipients remains unclear. This systematic review and network meta-analysis sought to assess the efficacy safety SOT recipients. We searched 6 databases from inception March 1, 2024 for randomized controlled trials (RCTs) observational studies evaluating different strategies Based patient-important outcomes, we performed frequentist random-effects pairwise meta-analyses meta-analyses, separating RCTs nonrandomized evidence, used Grading Recommendation, Assessment, Development, Evaluation approach our certainty evidence. included (N = 814) 43 125 199). Overall, there is a paucity evidence vaccines including infection, mortality, hospitalization, ICU admission, rejection, demonstrated low very due studies' risk bias. Throughout pandemic, clinicians worked with minimal, low-quality relation this population. In instance future public health emergencies, researchers should collaborate closely patient partners ensure sufficient population outcomes.

Язык: Английский

Процитировано

5
COVID-19 Outcomes and Vaccinations in Swedish Solid Organ Transplant Recipients 2020–2021: A Nationwide Multi-Register Comparative Cohort Study DOI Creative Commons
John Mackay Søfteland, Huiqi Li, Jesper Magnusson

и другие.

Viruses, Год журнала: 2024, Номер 16(2), С. 271 - 271

Опубликована: Фев. 8, 2024

Increased COVID-19-related morbidity and mortality have been reported in solid organ transplant recipients (SOTRs). Most studies are underpowered for rigorous matching. We report infections, hospitalization, ICU care, from COVID-19, pertinent vaccination data Swedish SOTRs 2020–2021. conducted a nationwide cohort study, encompassing all residents. were identified with ICD-10 codes immunosuppressant prescriptions. Comparison cohorts weighted based on propensity score built potential confounders (age, sex, comorbidities, socioeconomic factors, geography), which achieved good balance between non-SOTR groups. included 10,372,033 individuals, including 9073 SOTRs. Of the SARS-CoV-2 infected, 47.3% of 19% comparator individuals hospitalized. care was given to 8% infected 2% comparators. The case fatality rate 7.7% SOTRs, 6.2% comparison cohort, 1.3% unweighted cohort. had an increased risk contracting COVID-19 (HR = 1.15 p < 0.001), being hospitalized 2.89 receiving 4.59 dying 1.42 0.001). much higher than general population during Also compared comparators, hospitalized, dying. In Sweden, vaccinated earlier Lung worst outcomes. Excess among concentrated second half 2021.

Язык: Английский

Процитировано

4
Detection of Sars-Cov-2 Rnaemia in Patients with Immunodeficiency in the Post-Covid 19 Vaccination Era DOI

Anne Thierbach,

Veronica Di Cristanziano, Kirsten Alexandra Eberhardt

и другие.

Опубликована: Янв. 1, 2025

AbstractBackground: Immunocompromised individuals, hemato-oncologic diseases or post-transplantation included, are, due to impaired immune response, at increased risk for severe and prolonged COVID-19. Observational Studies showed that SARS-CoV-2 RNAemia has been associated with poorer prognosis higher disease severity.Objective: The aim of this study was investigate the occurrence its association anti-SARS-CoV-2 antibodies in immunocompromised COVID-19 patients. Risk factors were included analysis.Study design: A retrospective conducted 55 patients tested positive SARS-CoV-2, who received treatment monoclonal (mAb) between December 2021 March 2022. Serological virological tests performed before mAb administration clinical data collected from electronic health records.Results: Out patients, 35% RNAemia. present all reported fatal cases. It negative testing anti-RBD IgG, anti-S2 IgG a lower leukocyte count. No found previous vaccinations patients.Conclusion: underscores importance humoral response controlling replication. can serve as potential biomarker severity individuals. Therefore, it should be considered settings appropriate therapy decisions. Further research is needed evaluate pathophysiology implications immunodeficient

Язык: Английский

Процитировано

0
ORCHESTRA Delphi Consensus: Diagnostic and Therapeutic Management of SARS-CoV-2 Infection in Solid Organ Transplant Recipients DOI Creative Commons

Beatrice Tazza,

Natascia Caroccia,

Alice Toschi

и другие.

Clinical Microbiology and Infection, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
COVID-19 and Transplant Patients: Challenges, Risks, and Evolving Strategies DOI Creative Commons
Mariarosaria Campise

Vaccines, Год журнала: 2025, Номер 13(3), С. 318 - 318

Опубликована: Март 17, 2025

The first cases of COVID-19 were reported in December 2019 Wuhan, China [...]

Язык: Английский

Процитировано

0
The Impact and Evolution of COVID-19 on Liver Transplant Recipients Throughout the Pandemic “Waves” in a Single Center DOI Creative Commons
Clara Fernández Fernández,

Blanca Otero Torrón,

Mercedes Bernaldo de Quirós Fernández

и другие.

Viruses, Год журнала: 2025, Номер 17(2), С. 273 - 273

Опубликована: Фев. 16, 2025

Liver transplant recipients (LTRs) have been considered a population group that is vulnerable to COVID-19 as they are chronically immunosuppressed patients with frequent comorbidities. This study describes the course of SARS-CoV-2 disease from February 2020 December 2023 along seven pandemic "waves". We carried out an observational on 307 cases in cohort LTRs aim evaluating changes characteristics over time and determining risk factors for severe COVID-19. An older age serum creatinine level ≥ 2 mg/dL were found be hospital admission respiratory failure. The use calcineurin inhibitors was protective factor death, hospitalization, failure One hundred percent who died (N = 12) mycophenolate mofetil, which determinant Azathioprine associated intensive care unit (ICU) invasive mechanical ventilation (IMV). Vaccination failure, mortality. rate higher during first five waves, peak 57.14%, highest mortality (21.43%) occurred fourth wave. IMV ICU rates did not show significant differences across periods studied.

Язык: Английский

Процитировано

0